NRDL 2026 outlook: China drug pricing and market access

Published on June 8, 2026

The 2026 NRDL process has been well underway with a few notable tweaks, while the main themes on innovation and competition will feature more prominently than ever. 

Breaking away from the traditional timeline, the 2026 National Reimbursement Drug List (NRDL) started one month earlier than usual. New windows were also introduced for qualified candidates to discuss comparator choices with payer experts before dossier submission, and for candidates anticipating formal regulatory approvals to pre-submit their NRDL dossiers. 

Source: Simon-Kucher, NHSA, press release.

In early July, a record number of candidates made it through the qualifying round by passing the formal review process. 

  • A total of 368 drugs will be up for NRDL new listing, a marked increase from 310 candidates last year. 
  • Another 233 drugs…

    Simon-Kucher insights: NRDL 2026: What's changed, what's at stake

Continue reading on website
Other news

The next layer of value: AI strategy for data, information, and analytics businesses

June 8, 2026
AI is changing how customers use data: less like a destination they visit, and more as a layer inside their day-to-day workflows. That creates a clear opportunity for providers, but also a risk that valuable usage becomes embedded before it is properly priced or controlled. Providers that get the rights, access model, and pricing right can turn that risk into a new source of growth. AI is changing

Neobanking in the UK: Growth, limits, and what comes next

July 1, 2026
The UK has produced some of the world’s most successful neobanks, but domestic growth tells a more nuanced story. New results from our Neobanking Study reveal why high adoption has not yet translated into product depth and business model maturity, and what this means for the next phase of competition.The UK’s place in a global neobanking shiftGlobally, neobanks have moved beyond challenger status.